Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

Paricalcitol

1-month Paricalcitol 2mcg/day

OTHER

placebo

1-month Placebo Treatment

Trial Locations (6)

24020

Clinical Research Center fo Rare Diseases Aldo and Cele Daccò, Ranica

24030

ASL of Ponte San Pietro - Diabetologic Unit, Brembate

Unknown

Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo

Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases, Romano di Lombardia

Azienda Ospedaliera Bolognini - Unità di Medicina, Seriate

Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases, Treviglio

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT01393808 - Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes | Biotech Hunter | Biotech Hunter